Charcot-Marie-Tooth Disease
Return to Library
What is Charcot-Marie-Tooth disease?Charcot-Marie-Tooth disease is a group of progressive disorders that affect the peripheral nerves. Peripheral nerves connect the brain and spinal cord to muscles as well as sensory cells that detect sensations such as touch, pain, heat, and sound. Symptoms of Charcot-Marie-Tooth disease usually begin in adolescence or early adulthood, but onset may occur anytime from early childhood to mid-adulthood. Symptoms vary in severity. Some people never realize they have the disorder, but most have a moderate amount of physical disability, and a small percentage of people experience severe weakness. Many people with this disorder lead active lives and have normal life expectancies. Typically, the earliest symptoms involve muscle weakness in the feet, which can cause foot abnormalities such as high arches (pes cavus) or curled toes (hammer toes). It may become difficult to hold up the foot or to walk on the heel of the foot. These difficulties may cause a higher than normal step (or gait) and can increase the chance of ankle injuries and tripping. As the disease progresses, muscles in the lower legs usually weaken, but leg and foot problems rarely require the use of a wheelchair. Later symptoms may include muscle weakness in the hands, causing difficulty with daily activities such as writing, fastening buttons, and turning doorknobs. Because signals to sensory cells can be disrupted in Charcot-Marie-Tooth disease, people with this disorder may also notice some numbness, feel pain in the feet and lower legs, or experience a decreased sensitivity to heat and cold. In rare cases, sensory loss can include gradual hearing impairment and deafness. Different types of Charcot-Marie-Tooth disease can be distinguished by the abnormality that disrupts nerve function and by the genetic cause. Type X Charcot-Marie-Tooth disease is caused by mutations in a gene on the X chromosome, one of the two sex chromosomes. Type 1 Charcot-Marie-Tooth disease is characterized by abnormalities in myelin, the protective substance that covers nerve cells. Type 2 Charcot-Marie-Tooth disease is characterized by abnormalities in the fiber, or axon, that extends from a nerve cell and transmits nerve impulses. In intermediate forms of Charcot-Marie-Tooth disease, abnormalities occur in axons and myelin. Type 4 Charcot-Marie-Tooth disease affects either the axon or myelin. Types 1, 2, 4, and intermediate forms are further categorized by subtypes (such as 1A, 2A, 4A). Subtypes are distinguished by the specific gene that is altered. No universal system is used to classify types of Charcot-Marie-Tooth disease, and sometimes other names are used to describe this disorder. For example, Roussy-Levy syndrome is a form of type 1 Charcot-Marie-Tooth disease (type 1B). Dejerine-Sottas syndrome is a severe, early childhood form of Charcot-Marie-Tooth disease that may be type 1 or type 4 (depending on the specific gene that is altered). How common is Charcot-Marie-Tooth disease?Charcot-Marie-Tooth disease is the most common inherited disorder that involves the peripheral nerves, affecting an estimated 150,000 people in the United States. It occurs in all races and ethnic groups. Worldwide, this disorder affects about 1 in 3,300 people. What genes are related to Charcot-Marie-Tooth disease?Mutations in the BSCL2, DNM2, EGR2, GARS, GDAP1, GJB1, HSPB1, KIF1B, LITAF, LMNA, MFN2, MPZ, MTMR2, NDRG1, NEFL, PMP22, PRX, RAB7, SBF2, SH3TC2, and YARS genes cause Charcot-Marie-Tooth disease. Charcot-Marie-Tooth disease is caused by changes in one of several different genes that are essential to the function of nerves in the feet, legs, and hands. These changes impair axons that transmit nerve impulses or affect the specialized cells that produce myelin. As a result of these disrupted functions, nerve cells slowly lose the ability to stimulate the muscles and to transmit sensory signals. Increasingly, Charcot-Marie-Tooth disease is categorized by the specific gene that is altered. Type 1 is caused by mutations in the following genes: PMP22 (subtypes 1A and 1E), MPZ (subtype 1B), LITAF (subtype 1C), EGR2 (subtype 1D), and NEFL (subtype 1F). Alterations in the following genes cause type 2 Charcot-Marie-Tooth disease: KIF1B and MFN2 (subtype 2A), RAB7 (subtype 2B), LMNA (subtype 2B1), BSCL2 and GARS (subtype 2D), NEFL (subtype 2E), HSPB1 (subtype 2F), MPZ (subtypes 2I and 2J), and GDAP1 (subtype 2K). Type 4 Charcot-Marie Tooth disease is caused by mutations in the following genes: GDAP1 (subtype 4A), MTMR2 (subtype 4B1), SBF2 (subtype 4B2), SH3TC2 (subtype 4C), NDRG1 (subtype 4D), EGR2 (subtype 4E), and PRX (subtype 4F). Type X Charcot-Marie-Tooth disease is caused by a mutation in the GJB1 gene, and intermediate forms of the disorder are caused by an altered DNM2 or YARS gene. How do people inherit Charcot-Marie-Tooth disease?The pattern of inheritance varies with the type of Charcot-Marie-Tooth disease. Type 1, most cases of type 2, and intermediate forms of Charcot-Marie-Tooth disease are inherited in an autosomal dominant pattern. This pattern of inheritance means that one copy of the altered gene in each cell is sufficient to cause the disorder. In most cases, an affected person has one affected parent. Type 4 and subtypes 2B1 and 2K are inherited in an autosomal recessive pattern, which means two copies of the gene in each cell are altered. Most often, the parents of a child with an autosomal recessive disorder are not affected but are carriers of one copy of the altered gene. Type X is inherited in an X-linked dominant pattern. A condition is considered X-linked if the mutated gene that causes the disorder is located on the X chromosome. The inheritance is dominant if one copy of the altered gene is sufficient to cause the condition. In most cases, males experience more severe symptoms of the disorder than females. A striking characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons. Some cases of Charcot-Marie-Tooth disease result from a new mutation and occur in people with no history of the disorder in their family.
Source: National Institutes of Health
|
Free Charcot-Marie-Tooth Disease Articles |
- Reports from Ohio State University, Center for Molecular Neurobiology add new data to research in spinal muscular atrophy
- Research data from Johns Hopkins University, Department of Neurology update understanding of spinal muscular atrophy genetics
- Research from Stanford University in the area of spinal muscular atrophy prevention described
- Research from University of Texas broadens understanding of spinal muscular atrophy
- Research from University of Utah, Eccles Institute of Human Genetics broadens understanding of spinal muscular atrophy
- Research reports from Northwestern University, Research Center provide new insights into spinal muscular atrophy therapy
- Researchers from Medical University of South Carolina publish new studies and findings in the area of spinal muscular atrophy in children
- Researchers from University of Utah, Department of Neurology provide details of new studies and findings in the area of spinal muscular atrophy clinical trial
- New biomechanics study findings have been published by scientists at La Sapienza University
- Researchers from University of Verona describe findings in charcot-marie tooth disease
- Research from Istanbul University, Istanbul Faculty of Medicine provide new insights into neurology
- Reports summarize spinal muscular atrophy genetics research from L. Alias and co-authors
- Research from Rouen University, Institute for Biomedical Research has provided new information about biomedicine
- Studies from University of the Witwatersrand, National Health Laboratory Service reveal new findings on spinal muscular atrophy genetics
- Researchers from Capital Medical University, Department of Neurology detail new studies and findings in the area of neuroscience
- New spinal muscular atrophy research reported from College of Medicine
- Research from Cleveland Clinic broadens understanding of gene therapy
- Studies from Harvard University further understanding of spinal muscular atrophy therapy
- Studies in the area of spinal muscular atrophy reported from University of Wuerzburg, Institute for Clinical Neurobiology
|
|
|
Recent findings in spinal muscular atrophy genetics described by researchers from University of Utah
2007 OCT 8 -- Current study results from the report, 'Spinal muscular atrophy genetic counseling access and genetic knowledge: parents' perspectives,' have been published. "Spinal muscular atrophy is characterized by degeneration of alpha motor neurons in the anterior horns of the spinal cord, which leads to progressive symmetrical muscle weakness and atrophy. Spinal muscular atrophy is the leading fatal autosomal recessive disorder in infancy, and genetic counseling is an essential component of the care of families of these patients," researchers in the United States report. "However, little guidance is available in the published literature regarding the process and benefit of genetic counseling for families. Accordingly, the authors designed a questionnaire to assess parents' knowledge of the disease, gauge their access to genetic counseling, and determine how parents use information gained from counseling to guide choices for future pregnancies. The questionnaire specifically targeted when genetic counseling was received, from whom, parental knowledge regarding spinal muscular atrophy genetics, parental choices regarding spinal muscular atrophy and their child, frequency of prenatal testing, perceived relevance of newborn screening, and opinions regarding the disease. Most families clearly received some type of genetic counseling. Yet how and from whom they received the information varied greatly, as did their genetic knowledge of spinal muscular atrophy. The highest percentage of families received counseling from neurologists, who may not be appropriately prepared to provide formal genetic counseling. Many respondents reported having a negative experience with genetic counseling, possibly because it occurred at the time of diagnosis or shortly afterward, a period of great emotional turmoil," wrote C. Meldrum and colleagues, University of Utah. The researchers concluded: "These data suggest that a consistent approach for facilitating how and when genetic counseling is received is greatly needed.'." Meldrum and colleagues published their study in the Journal of Child Neurology (Spinal muscular atrophy genetic counseling access and genetic knowledge: parents' perspectives. Journal of Child Neurology, 2007;22(8):1019-26). For additional information, contact C. Meldrum, University of Utah School of Medicine, Salt Lake City, Utah 84132 USA.. Publisher contact information for the Journal of Child Neurology is: B C Decker Inc., 20 Hughson St. South, PO Box 620, L C D 1, Hamilton, Ontario L8N 3K7, Canada. Keywords: United States, Salt Lake City, Spinal Muscular Atrophy Genetics, Charcot-Marie-Tooth Disease, Child Neurology, Genetics, Neurology, Spinal Muscular Atrophy. This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2007, Pain & Central Nervous System Week via NewsRx.com.
|